New report showcases AI breakthroughs, diversity, and innovation for 2026
The brand-new edition of the 2026 Clinical Research Report examines key therapy areas and deep dives into the latest advances…
sponsored
-
-
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Author: Manny Vazquez, Senior Director Clinical Data Strategy, Veeva The number of data points collected in clinical trials has tripled…
-
ESMO 2025: Data, decisions, and the future of oncology
This year’s congress showcased remarkable progress across multiple fronts, from next-generation immunotherapies and antibody-drug conjugates (ADCs) to the accelerating role of AI-driven…
-
The future of high-potency APIs: Strategies for manufacturing challenges
The growing friction between the US and China has serious consequences for the supplies of high-potency active pharmaceutical ingredients (HPAPIs),…
-
Wearables and AI in Parkinson’s trials: Enriching endpoints for accurate, holistic assessments
Parkinson’s Disease is a complex, progressive neurological condition which requires challenging, multi-modal endpoint assessment across both motor and non-motor symptoms.…
-
Advanced bioconjugation strategies: New webinar tackles complex chemistry for targeted therapeutics
In the fast-paced environment of pharmaceutical innovation, bioconjugation has proved to be a cornerstone technology. By enabling the precise modification…
-
Productivity hurdles: Why identifying and rectifying site-specific challenges is key to improving clinical trials
“The question we must all ask ourselves is ‘What can we do to help sites overcome their challenges?’” asks John…
-
Cutting through the hype: Optimising AI in clinical data
Artificial intelligence (AI) has become one of the most talked-about technologies of our time, but when it comes to complex…
-
Podcast: Reflecting on 2025 trend predictions
This finale in the first Zelta Podcast series follows up on an article published on 8 January on Pharmaceutical-Technology.com and…
-
The landscape, projections, and secrets to success in immuno-oncology trials
The global immuno-oncology (IO) market has shown remarkable expansion over the past decade, reaching an unprecedented commercial scale and driving…
